Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2008

View Archived Issues

Hedgehog pathway inhibitor shows potential benefits in cancer models

LRG-47: a novel therapeutic target in multiple sclerosis

Low relapse rate and MRI activity in MS with oral FTY-720 in 30-month extension study

Lumiliximab activity is independent of antigen expression levels in lymphocytic leukemia cells

Nippon Shinyaku receives approval for dysmenorrhea agent in Japan

ABT-263 improves oral bioavailability and potency of Bcl-2 family protein inhibitors

Schering-Plough receives Japanese approval for Aroglycem

ARRY-520 enters phase I/II clinical evaluation

JAK2 inhibitor INCB-18424 to be evaluated in phase II studies

Boston Scientific receives Canadian approval for sale of Taxus Liberte coronary stent

BrainCells initiates phase II clinical trial of BCI-540 for depression with anxiety

Novel antithrombotic agents disclosed in recent Portola patent

Recent Schering patents divulge new analgesic agents

Romark initiates enrollment in phase II clinical trial of Alinia in hepatitis C

Preclinical activity of Aurora kinase B/C inhibitor GSK-1070916A described

CD-200-Fc significantly improves arthritis in mouse model

Alseres opens seven enrollment sites for first stage of Altropane phase III clinical trial program

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical sponge

CSL Behring submits NDS to Health Canada for approval of C1-esterase inhibitor for HAE

Raptor initiates phase IIa Convivia study in subjects with ALDH2 deficiency

Thalidomide Pharmion granted E.U. marketing authorization for multiple myeloma

Recent Speedel patent reports novel antihypertensive agents

Sutent approved in Japan for GIST and renal cell carcinoma

Champix set for Japanese launch

Bayer launches Nexavar in Japan for recurrent renal carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...